Mark Cook
0000-0001-8647-9208
Publication & Citation Trends
Most Cited Works
Publications
193 total
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial PDF
Cited by 436
OpenAlex
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial PDF
Cited by 114
OpenAlex
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma PDF
Cited by 973
OpenAlex
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Cited by 395
OpenAlex
A phase 2 study of <scp>SRT</scp>501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma
Cited by 214
OpenAlex
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis
Cited by 124
OpenAlex
Research Topics
Multiple Myeloma Research and Treatments
(102)
Protein Degradation and Inhibitors
(39)
Amyloidosis: Diagnosis, Treatment, Outcomes
(32)
CAR-T cell therapy research
(23)
Hematopoietic Stem Cell Transplantation
(21)
Frequent Co-Authors
Affiliations
National Health Service
Western University
NHS Blood and Transplant
University of Leeds
University Hospitals Birmingham NHS Foundation Trust